ClinicalTrials.gg
CompletedNCT01411137Updated Nov 7, 2019Results posted

Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study

A Phase 3 interventional study of IPX066 in Parkinson's Disease, sponsored by Impax Laboratories, LLC. Completed at 8 sites in United States. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2019-11-07.

Sponsored by Impax Laboratories, LLC (part of Amneal Pharmaceuticals, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. — 1 open to participants now, 1 under way, none of them phase 3. Parkinson Disease · Amneal Pharmaceuticals, Inc..

Enrollment
8th of 14
43 · median 77
Started
2011
the only one that year
Phase 3
7 of 14
none open now
Registered
9th of 14
by date

Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., this one is the 8th largest by enrollment, is the only one that started in 2011, is one of 7 in phase 3, and was the 9th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., or all of them as a file.
02

Study summary

The study had three distinct parts and is described as follows:

Part 1:

  • To evaluate the dose conversion from CD-LD ER taken alone or in combination with CD-LD IR to IPX066 in subjects with advanced PD
  • To evaluate the utility of the Objective Parkinson's Disease Measurement (OPDM), an exploratory computer-based system, in assessing dexterity and mobility in a subset of PD subjects.

Part 2:

  • To evaluate the long-term safety and clinical utility of IPX066 under open-label conditions in eligible subjects who successfully completed Part 1 of the study.

Part 3:

  • To further evaluate the long-term safety of IPX066 in eligible subjects who successfully completed Part 2.
Read the detailed description

Part 1: This study was a multicenter, open-label study. Subjects were to be converted from their previous CD-LD treatment to IPX066 over a 6-week period. Up to 40 subjects were to be enrolled in the study. Enrollment was defined as subjects who received study drug in Part 1 - Visit 1. Subjects were to be entered into one of two cohorts.

Approximately 24 subjects were to enroll in Cohort 1 (non-OPDM subjects) and up to 16 subjects at selected sites were to enroll in Cohort 2 (OPDM subjects). For the subjects enrolled in Cohort 2, along with the OPDM measurements, PK blood samples were also to be collected.

Part 2: Following the successful completion of Part 1 of the study, eligible subjects could participate in Part 2, a 6-month open-label extension study.

Part 3: Following the successful completion of Part 2 of the study, eligible subjects could participate in Part 3, an additional 6-month open-label extension study.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with idiopathic PD without any known cause for Parkinsonism.
  2. At least 30 years old at the time of PD diagnosis.
  3. Currently being treated with:

    • an LD dosing frequency of at least four times a day
    • at least one dose of CD-LD ER daily
    • requiring a total daily LD dose of at least 400 mg
    • stable regimen for at least 4 weeks prior to Screening
  4. Concomitant therapy with amantadine, anticholinergics, selective monoamine oxidase (MAO) type B inhibitors (e.g., selegiline, rasagiline) or dopamine agonists is allowed as long as the doses and regimens have been stable for at least 4 weeks prior to Screening and the therapy is intended to be constant throughout the course of the study.
  5. Agrees to use a medically acceptable method of throughout the study and for 1 month after completing the study.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding
  2. Diagnosed with atypical Parkinsonism or any known secondary Parkinsonian syndrome.
  3. Nonresponsive to LD therapy.
  4. Prior functional neurosurgical treatment for PD (e.g., ablation or deep brain stimulation) or if such procedures are anticipated during study participation.
  5. Planning to take during participation in the clinical study: any controlled-release LD product, additional CD or benserazide, entacapone or tolcapone, nonselective MAO inhibitors, or antipsychotics including neuroleptic agents for the purpose of treating psychosis or bipolar disorder.
  6. Any evidence of suicidal behavior within 6 months of entering the study.
  7. Allergic or hypersensitive to to CD, LD, entacapone, riboflavin, Yellow Dye #5 (tartrazine), citrus fruit or grape juice.
  8. History of or currently active psychosis.
  9. Active or history of peptic ulcers or surgical procedure of the stomach, the small intestine or the large intestine.
  10. Active or history of narrow-angle glaucoma.
  11. History of malignant melanoma or a suspicious undiagnosed skin lesion.
  12. History of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias, upper gastrointestinal hemorrhage, or neuroleptic malignant syndrome and/or nontraumatic rhabdomyolysis.
  13. Abnormal kidney function
  14. Severe hepatic impairment.
  15. Received any medications during the 4 weeks prior to Screening.
  16. Previously enrolled in IPX066 studies.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    IPX066

    Subjects were to receive individualized IPX066 doses orally in an open-label manner using four dosage strengths.

    Drug: IPX066

Interventions

  • DrugIPX066

    Subjects were converted from their current treatment to IPX066 over a 6-week period. Experimental Drug Product: IPX066 (carbidopa-levodopa) extended-release capsules

    Also known as: ER CD-LD

06

What researchers measure

Primary outcomes

  1. Patient Global Impression (PGI)

    At Part 1 Week 6, Part 2 Month 3 and Month 6 or at Early Termination, the subjects rated the change in their condition with IPX066 treatment from their condition prior to Part 1 Visit 1(Baseline) using Patient Global Impression (PGI) 7-point scale. 1=very much worse and 7=very much improved.

    Time frame: 6 months

  2. Clinical Global Impression (CGI)

    Clinician-reported satisfaction outcome of IPX066 using Clinical Global Impression (PGI) 7-point scale. At Part 1 Week 6; Part 2 Month 3, and Month 6 or at Early Termination, the Investigator rated how much a subject's overall condition had changed since Part 1 Visit 1 (Baseline) using 7-point scale. 1=very much worse and 7=very much improved.

    Time frame: 6 months

  3. Parkinson's Disease Questionnaire-8 (PDQ-8)

    Change from Baseline in Parkinson's disease Questionnaire-8 (PDQ-8) at End of Study or early discontinuation. The PDQ-8 is a self-reported questionnaire consisting of 8 questions regarding the subject's disease symptoms, each item ranging from 0 to 4, and the responses consist of 0=Never, 1=Occasionally, 2=Sometimes, 3=Often, and 4=Always or cannot do at all, total score ranging from 0 (never have problems/issues) to 32 (always have problems or cannot do at all).

    Time frame: 6 months

07

Results

Posted Apr 18, 2017

Participant flow

Date first subject enrolled: August 19, 2011 Date last subject completed: March 20, 2013

Part 1: Dose Conversion
Participant flow — Part 1: Dose Conversion
MilestoneIPX066
Started43
Completed33
Not completed10
Part 2: Open-Label Extension
Participant flow — Part 2: Open-Label Extension
MilestoneIPX066
Started32
Completed25
Not completed7
Part 3: Open-Label Extension
Participant flow — Part 3: Open-Label Extension
MilestoneIPX066
Started12
Completed12
Not completed0

Outcome measures

PrimaryPatient Global Impression (PGI)

At Part 1 Week 6, Part 2 Month 3 and Month 6 or at Early Termination, the subjects rated the change in their condition with IPX066 treatment from their condition prior to Part 1 Visit 1(Baseline) using Patient Global Impression (PGI) 7-point scale. 1=very much worse and 7=very much improved.

Time frame:
6 months
Reported as:
Mean · units on a scale
Patient Global Impression (PGI)
units on a scalePart 1: ConversionPart 2: Open-Label Extension (Month 3)Part 2: Open-Label Extension (Month 6)Part 1 or 2 Early Termination
Patient Global Impression (PGI)5.2 ± 1.355.4 ± 1.305.3 ± 1.492.8 ± 1.21
PrimaryClinical Global Impression (CGI)

Clinician-reported satisfaction outcome of IPX066 using Clinical Global Impression (PGI) 7-point scale. At Part 1 Week 6; Part 2 Month 3, and Month 6 or at Early Termination, the Investigator rated how much a subject's overall condition had changed since Part 1 Visit 1 (Baseline) using 7-point scale. 1=very much worse and 7=very much improved.

Time frame:
6 months
Reported as:
Mean · units on a scale
Clinical Global Impression (CGI)
units on a scalePart 1: ConversionPart 2: Open-Label Extension (Month 3)Part 2: Open-Label Extension (Month 6)Part 1 or 2 Early Termination
Clinical Global Impression (CGI)5.5 ± 1.155.7 ± 1.085.6 ± 1.393.7 ± 0.80
PrimaryParkinson's Disease Questionnaire-8 (PDQ-8)

Change from Baseline in Parkinson's disease Questionnaire-8 (PDQ-8) at End of Study or early discontinuation. The PDQ-8 is a self-reported questionnaire consisting of 8 questions regarding the subject's disease symptoms, each item ranging from 0 to 4, and the responses consist of 0=Never, 1=Occasionally, 2=Sometimes, 3=Often, and 4=Always or cannot do at all, total score ranging from 0 (never have problems/issues) to 32 (always have problems or cannot do at all).

Time frame:
6 months
Reported as:
Mean · units on a scale
Parkinson's Disease Questionnaire-8 (PDQ-8)
units on a scalePart 1: Conversion (Baseline)Part 1: Conversion (Week 6)Part 2: Open-Label Extension (Month 3)Part 2: Open-Label Extension (Month 6)Part 1 or 2 Early Termination
Parkinson's Disease Questionnaire-8 (PDQ-8)9.6 ± 5.498.1 ± 4.628.5 ± 4.799.0 ± 5.9111.8 ± 6.62

Adverse events

Collected over 58 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Conversion—1/43 (2.3%)18/43 (41.9%)
Part 2: Open-Label Extension 1—5/32 (15.6%)17/32 (53.1%)
Part 3: Open-Label Extension 2—3/12 (25%)9/12 (75%)
Overall—9/43 (20.9%)35/43 (81.4%)
Most frequent serious events
Most frequent serious events
EventPart 1: ConversionPart 2: Open-Label Extension 1Part 3: Open-Label Extension 2Overall
Orthostatic HypotensionVascular disorders0/430/322/122/43
Cerebrovascular accidentNervous system disorders0/431/321/122/43
Atrial FibrillationCardiac disorders1/431/320/121/43
Parkinson's diseaseNervous system disorders0/431/320/121/43
AnxietyPsychiatric disorders0/431/320/121/43
SepsisInfections and infestations0/431/320/121/43
Back PainMusculoskeletal and connective tissue disorders0/431/320/121/43
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPart 1: ConversionPart 2: Open-Label Extension 1Part 3: Open-Label Extension 2Overall
Upper Respiratory InfectionInfections and infestations3/435/320/128/43
FallInjury, poisoning and procedural complications3/432/322/125/43
Orthostatic HypotensionVascular disorders0/432/322/123/43
NauseaGastrointestinal disorders5/432/320/127/43
AnxietyPsychiatric disorders2/432/321/125/43
DyskinesiaNervous system disorders3/431/320/124/43
Drug ToxicityInjury, poisoning and procedural complications0/430/321/121/43
DepressionPsychiatric disorders0/430/321/121/43
Renal Failure AcuteRenal and urinary disorders1/431/321/122/43
Dermatitis ContactSkin and subcutaneous tissue disorders0/430/321/121/43

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)All Study Participants
<=18 years0
Between 18 and 65 years20
>=65 years23
Age, Continuous
Age, Continuous(years)All Study Participants
Mean66.4 ± 10.49
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female23
Male20
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Study Participants
Hispanic or Latino0
Not Hispanic or Latino43
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Study Participants
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White42
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)All Study Participants
United States43
08

Study locations

8 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Coastal Neurological Medical Group
    La Jolla, California 92037, United States
  • The Parkinson's Institute
    Sunnyvale, California 94085, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Quest Research Institute
    Bingham Farms, Michigan 48025, United States
  • University of Nevada School of Medicine
    Las Vegas, Nevada 89102, United States
  • Parkinson's Disease and Movement Disorders Center of Long Island
    Commack, New York 11725, United States
  • Wisconsin Institute for Neurologic and Sleep Disorders
    Milwaukee, Wisconsin 53233, United States
09

References and documents

Publications

  • Tetrud J, Nausieda P, Kreitzman D, Liang GS, Nieves A, Duker AP, Hauser RA, Farbman ES, Ellenbogen A, Hsu A, Kell S, Khanna S, Rubens R, Gupta S. Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. J Neurol Sci. 2017 Feb 15;373:116-123. doi: 10.1016/j.jns.2016.11.047. Epub 2016 Nov 23. PubMed 28131167 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 4 years 1 month after primary completion. A results delay was requested in Sep 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2011
First posted
Aug 8, 2011
Start
Aug 2011
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results delay requested
Sep 27, 2013
Results first posted
Apr 18, 2017
Last update
Nov 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01411137
Collaborators
Michael J. Fox Foundation for Parkinson's Research
Responsible party
Sponsor
First posted
Aug 8, 2011
Start date
Aug 2011
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Apr 18, 2017
Last update
Nov 7, 2019

Study contacts

Impax Study Director
study chair · Impax Laboratories, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion